I don't disagree with that because I think you misunderstood me. You are talking about the risk of getting a drug approved which of course decreases from phase 2 to phase 3 because phase 3 comes after phase 2. I was talking about the risk of failing to meet the primary endpoint of a phase 3 clinical trial in comparison with a phase 2 clinical trial.
bio shares dated 26/8/11, page-12
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.055(4.66%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.18 | $1.13 | $4.824M | 4.236M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25589 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |